Related Experiment Video
Updated: Sep 28, 2025

Transverse Aortic Constriction in Mice
Published on: April 21, 2010
RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1
Lin Yuan1,2,3,4, Shichen Bu1,2, Meng Du1,2
1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan 430022, Hubei, China.
Insights
Ring Finger Protein 207 (RNF207) worsens cardiac hypertrophy and dysfunction during pressure overload. Its inhibition protects the heart by impacting TAB1 ubiquitination and downstream signaling pathways.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Pathological cardiac remodeling, including cardiomyocyte hypertrophy and fibrosis, occurs under biomechanical stress like pressure overload.
- Ring Finger Protein 207 (RNF207), an E3 ubiquitin ligase highly expressed in the heart, has an unclear role in cardiac disease.
Purpose of the Study:
- To investigate the function of RNF207 in the development of pathological cardiac hypertrophy and dysfunction.
Main Methods:
- Cardiac hypertrophy was induced in mice via transverse aortic constriction (TAC).
- Cardiac function and remodeling were assessed using echocardiography, histology, and molecular analyses.
- In vitro studies utilized phenylephrine-induced cardiomyocyte hypertrophy and TAB1 knockdown models.
Main Results:
- RNF207 overexpression exacerbated TAC-induced cardiac hypertrophy, fibrosis, and systolic dysfunction.
- RNF207 knockdown significantly blunted cardiac remodeling in response to TAC.
- RNF207 promoted cardiomyocyte hypertrophy in vitro, which was dependent on TAB1.
- Mechanistically, RNF207 enhanced K63-linked ubiquitination of TAB1, activating the TAK1/p38/JNK signaling cascade.
Conclusions:
- RNF207 plays a critical role in exacerbating pressure overload-induced cardiac hypertrophy and dysfunction.
- RNF207 mediates its detrimental effects through the post-translational modification of TAB1, impacting key signaling pathways.
Aims:
The heart undergoes pathological remodelling, featured by the hypertrophic growth of cardiomyocytes and increased cardiac fibrosis, under biomechanical stress such as haemodynamic overload. Ring Finger Protein 207 (RNF207) is an E3 ubiquitin ligase that is predominantly expressed in the heart, but its function remains elusive. In this study, we aimed to explore the role of RNF207 in the development of pathological cardiac hypertrophy and dysfunction.
Methods And Results:
Transverse aortic constriction (TAC) surgery was performed on mice to induce cardiac hypertrophy. Cardiac function and remodelling were evaluated by echocardiography, histological assessment, and molecular analyses. Our data indicated that RNF207 overexpression (OE) exacerbated cardiac hypertrophy, fibrosis, and systolic dysfunction. In contrast, TAC-induced cardiac remodelling was profoundly blunted in RNF207 knockdown (KD) hearts. In line with the in vivo findings, RNF207 OE augmented, whereas RNF207 KD alleviated, phenylephrine-induced cardiomyocyte hypertrophy in vitro. Mechanistically, we demonstrated that RNF207 elicited detrimental effects by promoting K63-linked ubiquitination of TAK1-binding protein 1 (TAB1), which triggered the autophosphorylation of transforming growth factor-β activated kinase 1 (TAK1) and the activation of downstream p38 and c-Jun N-terminal kinase (JNK)1/2 signalling pathways. In the TAB1-KD cardiomyocytes, RNF207-OE-induced cell hypertrophy was significantly attenuated, indicating that RNF207-induced hypertrophy is, at least in part, TAB1-dependent.
Conclusions:
This study demonstrates that RNF207 exacerbates pressure overload-induced cardiac hypertrophy and dysfunction via post-translational modification of TAB1.
More Related Videos
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
MAPK Signaling Cascades
Heart Failure II: Pathophysiology
Abnormal Proliferation
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Rheumatic Heart Disease I: Introduction

